Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| B cell | 15 studies | 21% ± 7% | |
| fibroblast | 15 studies | 31% ± 9% | |
| endothelial cell | 15 studies | 27% ± 10% | |
| macrophage | 14 studies | 25% ± 11% | |
| natural killer cell | 12 studies | 21% ± 4% | |
| astrocyte | 12 studies | 41% ± 19% | |
| classical monocyte | 10 studies | 25% ± 10% | |
| oligodendrocyte | 9 studies | 60% ± 21% | |
| microglial cell | 9 studies | 38% ± 12% | |
| naive B cell | 8 studies | 21% ± 4% | |
| oligodendrocyte precursor cell | 8 studies | 39% ± 19% | |
| smooth muscle cell | 8 studies | 29% ± 11% | |
| GABAergic neuron | 7 studies | 49% ± 25% | |
| glutamatergic neuron | 7 studies | 54% ± 26% | |
| non-classical monocyte | 6 studies | 31% ± 11% | |
| monocyte | 6 studies | 22% ± 7% | |
| pericyte | 6 studies | 25% ± 6% | |
| myeloid cell | 6 studies | 42% ± 7% | |
| epithelial cell | 6 studies | 33% ± 12% | |
| retina horizontal cell | 6 studies | 28% ± 8% | |
| Mueller cell | 6 studies | 37% ± 13% | |
| conventional dendritic cell | 5 studies | 33% ± 16% | |
| mast cell | 5 studies | 28% ± 9% | |
| amacrine cell | 5 studies | 34% ± 7% | |
| retinal rod cell | 5 studies | 19% ± 3% | |
| T cell | 4 studies | 17% ± 2% | |
| neutrophil | 4 studies | 26% ± 7% | |
| CD4-positive, alpha-beta T cell | 4 studies | 22% ± 5% | |
| mature NK T cell | 4 studies | 18% ± 4% | |
| retinal ganglion cell | 4 studies | 33% ± 10% | |
| retinal bipolar neuron | 4 studies | 20% ± 2% | |
| retinal cone cell | 4 studies | 27% ± 9% | |
| dendritic cell | 4 studies | 35% ± 15% | |
| interneuron | 4 studies | 65% ± 22% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 22% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 25% ± 5% | |
| CD8-positive, alpha-beta T cell | 3 studies | 23% ± 3% | |
| memory B cell | 3 studies | 18% ± 1% | |
| precursor B cell | 3 studies | 23% ± 3% | |
| connective tissue cell | 3 studies | 21% ± 4% | |
| innate lymphoid cell | 3 studies | 18% ± 2% | |
| retinal pigment epithelial cell | 3 studies | 26% ± 6% | |
| adipocyte | 3 studies | 36% ± 12% | |
| GABAergic amacrine cell | 3 studies | 34% ± 9% | |
| glycinergic amacrine cell | 3 studies | 32% ± 3% | |
| type I pneumocyte | 3 studies | 22% ± 5% | |
| pancreatic A cell | 3 studies | 24% ± 3% | |
| neuron | 3 studies | 20% ± 3% | |
| gamma-delta T cell | 3 studies | 22% ± 5% | |
| immature B cell | 3 studies | 28% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 2171.26 | 245 / 245 | 100% | 14.89 | 501 / 502 |
| lung | 100% | 2893.90 | 578 / 578 | 100% | 11.99 | 1151 / 1155 |
| ovary | 100% | 3558.72 | 180 / 180 | 100% | 9.52 | 428 / 430 |
| breast | 100% | 2896.17 | 459 / 459 | 99% | 22.56 | 1111 / 1118 |
| brain | 99% | 1634.76 | 2623 / 2642 | 100% | 15.90 | 705 / 705 |
| esophagus | 100% | 2026.41 | 1445 / 1445 | 99% | 15.13 | 181 / 183 |
| thymus | 100% | 2091.64 | 653 / 653 | 98% | 12.75 | 595 / 605 |
| adrenal gland | 100% | 2305.30 | 258 / 258 | 98% | 13.99 | 226 / 230 |
| kidney | 100% | 1088.33 | 89 / 89 | 98% | 15.94 | 884 / 901 |
| stomach | 100% | 1658.31 | 359 / 359 | 98% | 13.28 | 280 / 286 |
| pancreas | 100% | 1216.05 | 327 / 328 | 98% | 12.05 | 174 / 178 |
| uterus | 100% | 2982.12 | 170 / 170 | 97% | 10.57 | 447 / 459 |
| intestine | 100% | 2137.49 | 966 / 966 | 97% | 11.50 | 512 / 527 |
| bladder | 100% | 2420.62 | 21 / 21 | 97% | 9.99 | 489 / 504 |
| liver | 100% | 1410.74 | 226 / 226 | 97% | 9.45 | 392 / 406 |
| skin | 100% | 2782.48 | 1809 / 1809 | 93% | 14.35 | 440 / 472 |
| adipose | 100% | 2980.26 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2310.15 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 2474.33 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2290.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 10.08 | 45 / 45 |
| peripheral blood | 99% | 3347.57 | 920 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 7.03 | 28 / 29 |
| heart | 97% | 1437.89 | 831 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 75% | 9.72 | 60 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_2000973 | Biological process | regulation of pro-B cell differentiation |
| GO_0001783 | Biological process | B cell apoptotic process |
| GO_0031929 | Biological process | TOR signaling |
| GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
| GO_0032007 | Biological process | negative regulation of TOR signaling |
| GO_0001932 | Biological process | regulation of protein phosphorylation |
| GO_0001934 | Biological process | positive regulation of protein phosphorylation |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0009267 | Biological process | cellular response to starvation |
| GO_0031334 | Biological process | positive regulation of protein-containing complex assembly |
| GO_1905672 | Biological process | negative regulation of lysosome organization |
| GO_1904263 | Biological process | positive regulation of TORC1 signaling |
| GO_0002327 | Biological process | immature B cell differentiation |
| GO_0002904 | Biological process | positive regulation of B cell apoptotic process |
| GO_0032008 | Biological process | positive regulation of TOR signaling |
| GO_0030183 | Biological process | B cell differentiation |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0019899 | Molecular function | enzyme binding |
| GO_0008047 | Molecular function | enzyme activator activity |
| GO_0051087 | Molecular function | protein-folding chaperone binding |
| GO_0042030 | Molecular function | ATPase inhibitor activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FNIP1 |
| Protein name | Folliculin-interacting protein 1 Folliculin interacting protein 1 |
| Synonyms | KIAA1961 |
| Description | FUNCTION: Binding partner of the GTPase-activating protein FLCN: involved in the cellular response to amino acid availability by regulating the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 . Required to promote FLCN recruitment to lysosomes and interaction with Rag GTPases, leading to activation of the non-canonical mTORC1 signaling . In low-amino acid conditions, component of the lysosomal folliculin complex (LFC) on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, thereby inactivating mTORC1 and promoting nuclear translocation of TFEB and TFE3 (By similarity). Upon amino acid restimulation, disassembly of the LFC complex liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent inactivation of TFEB and TFE3 . Together with FLCN, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy . In addition to its role in mTORC1 signaling, also acts as a co-chaperone of HSP90AA1/Hsp90: following gradual phosphorylation by CK2, inhibits the ATPase activity of HSP90AA1/Hsp90, leading to activate both kinase and non-kinase client proteins of HSP90AA1/Hsp90 . Acts as a scaffold to load client protein FLCN onto HSP90AA1/Hsp90 . Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins . Also acts as a core component of the reductive stress response by inhibiting activation of mitochondria in normal conditions: in response to reductive stress, the conserved Cys degron is reduced, leading to recognition and polyubiquitylation by the CRL2(FEM1B) complex, followed by proteasomal (By similarity). Required for B-cell development . . |
| Accessions | J3KNG8 ENST00000307954.12 ENST00000511848.1 [Q8TF40-2] ENST00000307968.11 [Q8TF40-3] Q8TF40 ENST00000510461.6 [Q8TF40-1] |